Cited by 174Parathyroid Disorders and TreatmentsDermatological and Skeletal DisordersAtherosclerosis and Cardiovascular Diseases

Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice.

Open access
Shao, Jian-Su, Cheng, Su-Li, Charlton-Kachigian, Nichole, Loewy, Arleen P., Towler, Dwight A.·2003·Journal of Biological Chemistry

Abstract

Cardiovascular calcification is a common consequence of diabetes. High fat diets induce diabetes and arterial calcification in male low density lipoprotein receptor (LDLR) -/- mice; calcification occurs via Msx2 signaling that promotes the osteogenic differentiation of arterial myofibroblasts. We studied regulation of arterial osteogenesis by human parathyroid hormone (PTH) (1-34) (also called teriparatide) in LDLR -/- mice fed diabetogenic diets for 4 weeks. LDLR -/- mice were treated with vehicle or 0.4 mg/kg of PTH(1-34) subcutaneously five times/week. Gene expression was determined from single aortas and hind limb RNA by fluorescence reverse transcription-PCR. Valve calcification was determined by histological staining of cardiac sections using image analysis to quantify valve leaflet mineralization. PTH(1-34) increased bone mineral content (by dual energy x-ray absorptiometry) in LDLR -/- mice, with induction of osseous osteopontin (OPN) expression and serum OPN levels (>150 nM); PTH(1-34) did not significantly change serum glucose, lipids, body weight, or fat mass. PTH(1-34) suppressed aortic OPN and Msx2 expression >50% and decreased cardiac valve calcification 80% (8.3 +/- 1.5% versus 1.4 +/- 0.5%; p < 0.001). Of the known circulating regulators of vascular calcification (OPN, osteoprotegerin, and leptin), PTH(1-34) regulated only serum OPN. We therefore studied actions of PTH(1-34) and OPN in vitro on cells induced to mineralize with Msx2. OPN (5-50 nM) reversed Msx2-induced mineralization. PTH(1-34) inhibited mineralization by 40% and down-regulated Msx2 in aortic myofibroblasts. PTH(1-34) inhibits vascular calcification and aortic osteogenic differentiation via direct actions and potentially via circulating OPN. PTH(1-34) exerts beneficial actions at early stages of macrovascular disease responses to diabetes and dyslipidemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m308825200

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Ory, D. S., Neugeboren, B. A., and Mulligan, R. C. (1996) Proc. Natl. Acad. Sci.

Cited by

Sorted by citations

Authors
Shao, J.-S., Cheng, S.-L., Charlton-Kachigian, N., Loewy, A. P., & Towler, D. A.
Affiliations
Barnes-Jewish Hospital (US)
Corresponding author
Towler, Dwight A.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2003-12
Volume
278
Issue
50
Pages
50195-50202
ISSN
0021-9258 (ISSN-L)
OpenAlex
W1974287326
Cited by
174
References
55
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 6 · 2019: 8 · 2018: 8 · 2017: 9 · 2016: 3 · 2015: 5 · 2014: 12 · 2013: 7 · 2012: 8
FWCI
7.48
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (HL-69229, R01HL069229)
Topics
  • Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
teriparatide, human parathyroid hormone (1-34), vascular calcification, osteogenic differentiation, Msx2, osteopontin, Ldlr-deficient mice, diabetes mellitus, valve calcification, bone mineral content, dyslipidemia, macroangiopathy
MeSH terms
Animals, Aorta, Calcium, Cell Differentiation, Diabetes Mellitus, DNA-Binding Proteins, Fibroblasts, Hyperlipidemias, Male, Models, Biological, Osteogenesis, Receptors, LDL, RNA, Sialoglycoproteins, Spectrometry, X-Ray Emission, Signal Transduction, Down-Regulation, Up-Regulation, Gene Expression, Homeodomain Proteins, Teriparatide, Reverse Transcriptase Polymerase Chain Reaction, Mice, Osteopontin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review